Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q3 EPS of $0.21, $0.63 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $71.75 million versus the consensus estimate of $16.25 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.